About the Company:
Senores Pharmaceuticals Limited is a Gujarat-based pharmaceutical firm known for its advanced formulations and growing global footprint. With headquarters in Ahmedabad, the company operates out of One42 Tower, South Wing, and continues to expand its influence in regulated markets across the globe.
-
📍 Address: One42, Ambali Bopal Road, Ahmedabad, Gujarat
-
☎️ Phone: +91 79 2999 9857
-
🌐 Website: www.senorespharma.com
-
🆔 CIN: U24290GJ2017PLC100263
-
📄 BSE Code: 544319
-
📄 NSE Symbol: SENORES
📜 Summary:
On April 3, 2025, Senores Pharmaceuticals Limited filed a regulatory disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This annual disclosure, issued by the company’s Promoter and Promoter Group, outlines the encumbrance on shares held directly or indirectly during FY 2024–25. These declarations are essential to maintain transparency regarding the financial obligations or collateral arrangements involving promoter holdings.
This regulatory compliance reflects the company’s commitment to shareholder transparency. However, it also alerts investors to the fact that promoter shares may have been pledged, which could indicate borrowing or financial leveraging. While this isn’t inherently negative, retail investors should track such developments, as they can signal future stock volatility or control dilution.
📌 Key Points:
-
🗓 Date of Disclosure: April 3, 2025
-
🏢 Company: Senores Pharmaceuticals Limited
-
📋 Subject: Annual Disclosure under Regulation 31(4), SEBI SAST Regulations
-
👤 Filed By: Vinay Kumar Mishra, Company Secretary
-
📩 Purpose: Informing about encumbrance (pledging) of promoter shares during FY 2024–25
-
🔍 Promoter Involved: Swapnil Shah
-
📊 Implication: Potential leverage or debt by promoters
-
🧾 Regulation Cited: SEBI (SAST) Regulations, 2011
📈 Effect on the Share Market:
-
📉 Short-term Impact: Market may react cautiously due to perceived promoter dependency on financing
-
🧐 Investor Perception: Could lead to lower investor confidence if not clarified by management
-
🔄 Liquidity Risks: If pledged shares are called in, it may cause price disruption
-
🔒 Volatility: Heightened volatility likely until encumbrance status is better understood
-
✅ Positive View: The company’s proactive disclosure may assure institutional investors of governance standards
👥 How This Helps Retail Traders:
-
📘 Transparency: Enables informed decisions by retail investors
-
📊 Risk Assessment: Allows evaluation of promoter commitment and financial exposure
-
📈 Trend Spotting: Offers early indication of potential stock movement
-
🧠 Educational Value: Educates traders on regulatory filings and their meanings
💬 Chat-Style demo:
User: What’s up with Senores Pharma’s recent filing?
ChatGPT: They’ve disclosed that promoter shares were pledged during FY 2024–25 as per SEBI norms.
User: Should I be worried?
ChatGPT: Not necessarily—but stay alert. Pledged shares mean the promoters have leveraged their stake, which could impact stock stability.
User: What should I do?
ChatGPT: Keep a watch on future filings, and make sure promoter pledging doesn’t increase. It’s good they disclosed it transparently.
🗨️ Phrase:
“Ever wondered what promoter share pledging really means? Let’s break it down – and see how it affects YOU.”
📊 Current Share Price
-
NSE (SENORES): ₹508.60
-
BSE (544319): ₹507.50
-
Time: 03:31 PM IST
-
Change: -₹9.20 (-1.78%) from the previous close of ₹516.70
📈 Key Metrics
-
52-Week High: ₹665.00
-
52-Week Low: ₹435.25
-
Market Capitalization: ₹2,337 crore
-
P/E Ratio (TTM): 74.36
-
EPS (TTM): ₹6.84
-
P/B Ratio: 3.05
📉 Recent Performance
-
1-Day Change: -1.78%
-
1-Month Change: -11.20%
-
3-Month Change: -1.00%
📉 Stock Market Disclaimer
Disclaimer: This post is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy/sell any stock or share. Investing in the stock market involves risk. Past performance is not indicative of future results. Always conduct your own research or consult a licensed financial advisor before making investment decisions.
